HC Wainwright Forecasts Traws Pharma Q4 Earnings

Traws Pharma, Inc. (NASDAQ:TRAW) – Equities researchers at HC Wainwright issued their Q4 2025 EPS estimates for shares of Traws Pharma in a research note issued on Wednesday, December 3rd. HC Wainwright analyst B. Folkes forecasts that the company will post earnings of ($1.91) per share for the quarter. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. HC Wainwright also issued estimates for Traws Pharma’s Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.54) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.56) EPS and FY2029 earnings at $0.49 EPS.

Traws Pharma (NASDAQ:TRAW) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($9.16) by $8.82. Traws Pharma had a net margin of 3,028.25% and a negative return on equity of 2,883.04%.

Several other research analysts have also recently issued reports on TRAW. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Traws Pharma in a research report on Monday. Wall Street Zen raised Traws Pharma to a “hold” rating in a report on Saturday, November 1st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $8.00.

Traws Pharma Price Performance

NASDAQ:TRAW opened at $2.11 on Thursday. Traws Pharma has a 12 month low of $0.97 and a 12 month high of $19.44. The firm has a market capitalization of $16.86 million, a PE ratio of 0.02 and a beta of 1.74. The business’s fifty day moving average price is $2.39 and its 200 day moving average price is $1.86.

Hedge Funds Weigh In On Traws Pharma

A number of hedge funds have recently modified their holdings of the business. Two Sigma Investments LP boosted its stake in Traws Pharma by 37.1% during the 3rd quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after purchasing an additional 5,955 shares during the period. Vestal Point Capital LP raised its holdings in shares of Traws Pharma by 133.3% in the first quarter. Vestal Point Capital LP now owns 175,000 shares of the company’s stock valued at $402,000 after buying an additional 100,000 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in shares of Traws Pharma during the first quarter worth about $759,000. 7.95% of the stock is currently owned by hedge funds and other institutional investors.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.